{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:09Z","timestamp":1753892109984,"version":"3.41.2"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2020.00518","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:37:40Z","timestamp":1591162660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Anna M. D.","family":"Watson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor A. M.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah C.","family":"Moody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadharshini","family":"Sivakumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karly C.","family":"Sourris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryna S. M.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Ko\u00eftka-Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri J.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin A. M.","family":"Jandeleit-Dahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna C.","family":"Calkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.5551\/jat.9084","article-title":"Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.","volume":"18","author":"Abe","year":"2011","journal-title":"J. Atheroscler. Thromb."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2337\/diacare.20.11.1683","article-title":"Prospective diabetes study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex.","volume":"20","year":"1997","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1136\/bmj.294.6588.1651","article-title":"Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus.","volume":"294","author":"Borch-Johnsen","year":"1987","journal-title":"Br. Med. J."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162731","article-title":"Renoprotective effects of atorvastatin in diabetic mice: downregulation of RhoA and upregulation of Akt\/GSK3.","volume":"11","author":"Bruder-Nascimento","year":"2016","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s00125-005-0102-6","article-title":"Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.","volume":"49","author":"Calkin","year":"2006","journal-title":"Diabetologia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00125-008-1060-6","article-title":"The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.","volume":"51","author":"Calkin","year":"2008","journal-title":"Diabetologia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.cir.0000021122.63813.32","article-title":"Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.","volume":"106","author":"Candido","year":"2002","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/clinchem\/40.7.1317","article-title":"Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia.","volume":"40","author":"Cefalu","year":"1994","journal-title":"Clin. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"49142","DOI":"10.1074\/jbc.m104879200","article-title":"A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion.","volume":"276","author":"Chen","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1523-1755.2004.00367.x","article-title":"Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.","volume":"65","author":"Chow","year":"2004","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the collaborative atorvastatin diabetes study (CARDS).","volume":"54","author":"Colhoun","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2337\/dc09-0191","article-title":"Cystatin C, albuminuria, and mortality among older adults with diabetes.","volume":"32","author":"de Boer","year":"2009","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States.","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1194\/jlr.r066514","article-title":"Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment.","volume":"57","author":"Ertunc","year":"2016","journal-title":"J. Lipid Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cmet.2017.01.004","article-title":"Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease.","volume":"25","author":"Falkevall","year":"2017","journal-title":"Cell Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/j.1523-1755.2004.00919.x","article-title":"Effect of fluvastatin on renal end points in the assessment of lescol in renal transplant (ALERT) trial.","volume":"66","author":"Fellstrom","year":"2004","journal-title":"Kidney Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/laban.1222","article-title":"Microbiota and reproducibility of rodent models.","volume":"46","author":"Franklin","year":"2017","journal-title":"Lab. Anim."},{"key":"B20","doi-asserted-by":"crossref","first-page":"F528","DOI":"10.1152\/ajprenal.00127.2010","article-title":"The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.","volume":"299","author":"Giunti","year":"2010","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cmet.2012.04.001","article-title":"Inflammation and lipid signaling in the etiology of insulin resistance.","volume":"15","author":"Glass","year":"2012","journal-title":"Cell Metab."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162131","article-title":"Mouse models of diabetes, obesity and related kidney disease.","volume":"11","author":"Glastras","year":"2016","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000073942","article-title":"Nephropathy in a hypercholesterolemic mouse model with streptozotocin-induced diabetes.","volume":"26","author":"Hammad","year":"2003","journal-title":"Kidney Blood Press Res."},{"key":"B24","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease.","volume":"25","author":"Haynes","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/01.hjh.0000184747.41565.a1","article-title":"Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.","volume":"23","author":"Jandeleit-Dahm","year":"2005","journal-title":"J. Hypertens."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1681\/asn.2013070810","article-title":"Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.","volume":"25","author":"Jha","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"B27","first-page":"3658","article-title":"Deficiency of hypoxia inducible factor-1alpha promoted progression of diabetic nephropathy with hypertension.","volume":"16","author":"Jiao","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153965","article-title":"Beneficial effects of sarpogrelate and rosuvastatin in high fat diet\/streptozotocin-induced nephropathy in Mice.","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1161\/01.hyp.25.5.1111","article-title":"A noninvasive computerized tail-cuff system for measuring blood pressure in mice.","volume":"25","author":"Krege","year":"1995","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1681\/asn.2004050392","article-title":"Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.","volume":"16","author":"Lassila","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1097\/01.asn.0000133025.23732.46","article-title":"Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.","volume":"15","author":"Lassila","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-016-0222-x","article-title":"Gut microbiota dysbiosis contributes to the development of hypertension.","volume":"5","author":"Li","year":"2017","journal-title":"Microbiome"},{"key":"B33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1900\/rds.2015.12.134","article-title":"Targeting mitochondria and reactive oxygen species-driven pathogenesis in diabetic nephropathy.","volume":"12","author":"Lindblom","year":"2015","journal-title":"Rev. Diabet Stud."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2017.001082","article-title":"The role of gut microbiota in atherosclerosis and hypertension.","volume":"9","author":"Ma","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1161\/circulationaha.116.024545","article-title":"High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice.","volume":"135","author":"Marques","year":"2017","journal-title":"Circulation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1681\/asn.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B37","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1046\/j.1523-1755.1999.07113.x","article-title":"Effect of lipoproteins on mesangial cell proliferation.","volume":"71","author":"Nishida","year":"1999","journal-title":"Kidney Int. Suppl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1007\/s00125-015-3596-6","article-title":"Peptide-based inhibition of IkappaB kinase\/nuclear factor-kappaB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.","volume":"58","author":"Oguiza","year":"2015","journal-title":"Diabetologia"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1038\/srep28882","article-title":"Osteopontin deficiency reduces kidney damage from hypercholesterolemia in apolipoprotein E-deficient mice.","volume":"6","author":"Pei","year":"2016","journal-title":"Sci. Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/s0003-9861(02)00496-4","article-title":"Synthetic ceramides induce growth arrest or apoptosis by altering cellular redox status.","volume":"407","author":"Phillips","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2215\/cjn.09320913","article-title":"Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study.","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1172\/jci27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J. Clin. Invest."},{"key":"B43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/ndt\/gfn626","article-title":"Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine.","volume":"24","author":"Song","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2017.001395","article-title":"Characterising an alternative murine model of diabetic cardiomyopathy.","volume":"10","author":"Tate","year":"2019","journal-title":"Front. Physiol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12192","article-title":"Nox-4 deletion reduces oxidative stress and injury by PKC-alpha-associated mechanisms in diabetic nephropathy.","volume":"2","author":"Thallas-Bonke","year":"2014","journal-title":"Physiol. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2017.00231","article-title":"Critical role of the interaction gut Microbiota - sympathetic nervous system in the regulation of blood pressure.","volume":"10","author":"Toral","year":"2019","journal-title":"Front. Physiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ame2.12022","article-title":"The role of the gut microbiota on animal model reproducibility.","volume":"1","author":"Turner","year":"2018","journal-title":"Anim. Model. Exp. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1042\/cs20120198","article-title":"Inflammation and the pathogenesis of diabetic nephropathy.","volume":"124","author":"Wada","year":"2013","journal-title":"Clin. Sci."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-018-1068-6","article-title":"Diabetic dyslipidemia: epidemiology and prevention of cardiovascular disease and implications of newer therapies.","volume":"20","author":"Warraich","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.2337\/db11-1546","article-title":"Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice.","volume":"61","author":"Watson","year":"2012","journal-title":"Diabetes"},{"key":"B53","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00125-009-1540-3","article-title":"The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.","volume":"53","author":"Watson","year":"2010","journal-title":"Diabetologia"},{"key":"B54","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.LAB.0000022222.03120.D4","article-title":"Renal injury in apolipoprotein E-deficient mice.","volume":"82","author":"Wen","year":"2002","journal-title":"Lab. Invest."},{"key":"B55","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ki.2014.286","article-title":"Reduced Kruppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy.","volume":"87","author":"Zhong","year":"2015","journal-title":"Kidney Int."},{"key":"B56","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10719-016-9693-z","article-title":"Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?","volume":"33","author":"Zhuang","year":"2016","journal-title":"Glycoconj. J."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2020.00518\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:37:45Z","timestamp":1591162665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2020.00518\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":56,"alternative-id":["10.3389\/fphys.2020.00518"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2020.00518","relation":{},"ISSN":["1664-042X"],"issn-type":[{"type":"electronic","value":"1664-042X"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"article-number":"518"}}